"We prioritize working with the best partners in this industry and Novamind's U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics," says Payton Nyquvest, Founder and CEO, Numinus. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. "Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. ("Novamind") (CSE: NM) (OTCQB: NVMDF) (FSE: HN2), are pleased to announce that they have entered into a definitive arrangement agreement (the "Agreement") pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind (the "Novamind Shares") in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately C$26.2 million on a fully diluted in-the-money basis (the "Transaction").įollowing the Transaction, the combined company will operate 13 wellness clinics and will be positioned as a leading psychedelic-assisted therapy provider in North America, leading its peer group in revenue with approximately C$10 million in annual pro-forma revenue based on the trailing four quarters. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) and Novamind Inc. VANCOUVER, BC and TORONTO, Ap/PRNewswire/ - Numinus Wellness Inc. Transaction expected to close in June 2022, following anticipated shareholder approval.Acquisition is expected to generate C$3 million in annual cost synergies.Combined C$10 million in annual pro-forma revenue based on the trailing four quarters.Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah).Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare.Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory.
0 kommentar(er)
